Global Conference on Medical and Health Sciences
Hosted Online from Madrid, Spain
Date: 14th April, 2026
Website: https://econferencia.com

MITOCHONDRIAL DYSFUNCTION IN NEUROLOGICAL DISORDERS: MECHANISTIC INSIGHTS AND EMERGING THERAPEUTIC TARGETS FOR PRECISION NEUROPROTECTION

Amirqulov Rahmatilla
Xayrullayev Islomjon
Tashkent State Medical University, Tashkent, Uzbekistan

Abstract

Mitochondrial dysfunction has emerged as a central pathological mechanism underlying a wide range of neurological disorders, including Alzheimer's disease, Parkinson's disease, stroke, and amyotrophic lateral sclerosis. As the primary source of cellular energy and a key regulator of metabolic homeostasis, mitochondria play a critical role in maintaining neuronal function and survival. Disruption of mitochondrial dynamics, bioenergetics, and signaling pathways leads to impaired energy production, increased oxidative stress, and activation of cell death pathways.

This study investigates the role of mitochondrial dysfunction in neurological disorders, focusing on its molecular mechanisms and potential as a therapeutic target. A translational analytical framework was employed to integrate findings from molecular biology, cellular neuroscience, and clinical research.

The results indicate that mitochondrial impairment contributes to neuronal damage through mechanisms such as ATP depletion, excessive generation of reactive oxygen species, disruption of calcium homeostasis, and activation of apoptotic pathways. Additionally, alterations in mitochondrial dynamics, including fission, fusion, and mitophagy, were identified as key factors in disease progression.

Emerging therapeutic strategies targeting mitochondrial function—including antioxidant therapies, mitochondrial biogenesis enhancers, and modulators of mitochondrial dynamics—show promise in preclinical and clinical studies. However, challenges remain in translating these approaches into effective treatments due to the complexity of mitochondrial biology.

In conclusion, mitochondrial dysfunction represents a critical driver of neurological disease progression, offering new insights into disease mechanisms and potential avenues for targeted therapeutic intervention.

Keywords: Mitochondria; Neurodegeneration; ATP depletion; Oxidative stress; Mitophagy; Mitochondrial dynamics; Neuroprotection; Calcium homeostasis; Therapeutic targets; Neurology

Introduction

Mitochondria are essential organelles that play a central role in cellular energy metabolism, redox regulation, and apoptotic signaling, making them critical determinants of neuronal function and survival. In the central nervous system (CNS), neurons exhibit exceptionally high metabolic demands, relying heavily on mitochondrial oxidative phosphorylation for ATP production. This dependence renders neuronal cells particularly vulnerable to mitochondrial dysfunction, which has increasingly been recognized as a fundamental contributor to the pathogenesis of various neurological disorders.

Traditionally, neurological diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis have been primarily associated with protein aggregation, synaptic dysfunction, and neuronal loss. However, growing evidence suggests that mitochondrial impairment is not merely a secondary consequence of these pathological processes but a key upstream factor that

actively drives disease progression. Disruptions in mitochondrial bioenergetics, dynamics, and signaling pathways have been consistently observed across a wide spectrum of neurological conditions, indicating a shared mechanistic basis.

One of the primary consequences of mitochondrial dysfunction is the impairment of ATP production. Neurons require a continuous and substantial supply of energy to maintain ion gradients, synaptic transmission, and intracellular signaling. Reduced ATP availability compromises these processes, leading to impaired neuronal function and increased susceptibility to damage. Additionally, dysfunctional mitochondria produce excessive reactive oxygen species (ROS), contributing to oxidative stress and further exacerbating cellular injury.

Mitochondria also play a critical role in calcium homeostasis, regulating intracellular calcium levels that are essential for neuronal signaling and plasticity. Dysregulation of mitochondrial calcium handling can lead to calcium overload, triggering the activation of proteases, lipases, and other enzymes that contribute to cellular damage and apoptosis. This mechanism is particularly relevant in neurodegenerative diseases, where calcium imbalance is a common pathological feature.

Another important aspect of mitochondrial function is the regulation of mitochondrial dynamics, including processes such as fission, fusion, and mitophagy. These processes are essential for maintaining mitochondrial quality and adaptability in response to cellular stress. Imbalances in mitochondrial dynamics can lead to the accumulation of damaged mitochondria, impaired energy production, and activation of cell death pathways. In diseases such as Parkinson's disease, mutations affecting proteins involved in mitophagy highlight the critical role of mitochondrial quality control in neuronal survival.

The interplay between mitochondrial dysfunction and other pathological mechanisms further amplifies its impact on neurological disorders. Mitochondrial

impairment is closely linked to oxidative stress, neuroinflammation, and protein aggregation, creating a complex network of interdependent processes that drive disease progression. For example, increased ROS production can promote protein misfolding, while inflammatory signaling can further disrupt mitochondrial function, forming a self-reinforcing cycle of cellular damage.

From a translational perspective, mitochondrial dysfunction represents a promising target for therapeutic intervention. Strategies aimed at restoring mitochondrial function, enhancing biogenesis, reducing oxidative stress, and improving mitochondrial dynamics are being активно investigated. Advances in molecular biology and pharmacology have led to the development of novel therapeutic agents targeting specific aspects of mitochondrial dysfunction, offering new opportunities for precision neuroprotection.

Despite these advances, several challenges remain in translating mitochondrial research into effective clinical treatments. The complexity of mitochondrial biology, variability in disease mechanisms, and differences in patient responses complicate the development of universally effective therapies. Additionally, targeting mitochondria without disrupting their essential physiological functions requires a high degree of specificity and precision.

Given these challenges and opportunities, there is a growing need for comprehensive investigation of mitochondrial dysfunction in neurological disorders. Understanding how mitochondrial processes contribute to disease initiation and progression is essential for developing targeted and effective therapeutic strategies.

In this context, the present study aims to explore mitochondrial dysfunction in neurological disorders, focusing on its molecular mechanisms, impact on neuronal survival, and potential as a target for emerging therapeutic interventions within a translational framework.

Materials and Methods

This study was designed as a comprehensive translational and integrative investigation aimed at analyzing mitochondrial dysfunction in neurological disorders, with a specific focus on its molecular mechanisms and emerging therapeutic targets. The methodological framework combines systematic literature synthesis, comparative evaluation of experimental and clinical findings, and translational interpretation linking mitochondrial biology to disease progression and therapeutic innovation. This multi-level approach ensures both scientific rigor and clinical relevance.

A structured and reproducible literature search was conducted across major scientific databases, including PubMed, Scopus, and Web of Science, covering publications from 2018 to 2025. The search strategy was developed to capture interdisciplinary research at the intersection of mitochondrial biology, neuroscience, and clinical neurology. Key search terms included “mitochondrial dysfunction,” “neurodegeneration,” “ATP depletion,” “oxidative stress,” “mitophagy,” “mitochondrial dynamics,” and “therapeutic targets.” Boolean operators (AND, OR) were systematically applied to refine search results and ensure comprehensive retrieval of relevant studies.

Following the initial database search, a multi-stage screening process was implemented. Titles and abstracts were first reviewed to exclude irrelevant, duplicate, or non-peer-reviewed studies. Subsequently, full-text articles were assessed based on predefined inclusion and exclusion criteria. Studies were included if they (i) investigated mitochondrial mechanisms in the central nervous system, (ii) provided molecular, cellular, or clinical evidence linking mitochondrial dysfunction to neurological disorders, and (iii) reported measurable outcomes such as ATP production, ROS generation, mitochondrial

dynamics, or clinical progression. Studies focusing solely on non-neuronal systems, lacking methodological clarity, or published prior to 2018 were excluded.

Data extraction was performed using a standardized analytical framework to ensure consistency across studies. Extracted variables included study design (experimental, clinical, or translational), type of neurological disorder (e.g., Alzheimer's disease, Parkinson's disease, stroke, amyotrophic lateral sclerosis), key mitochondrial parameters (e.g., ATP levels, ROS production, mitochondrial membrane potential, calcium homeostasis), and associated molecular pathways (e.g., fission/fusion balance, mitophagy regulation, apoptotic signaling). Additional data regarding sample size, experimental models, and therapeutic interventions targeting mitochondrial function were also collected.

To facilitate structured analysis, the selected studies were categorized into three primary domains:

(1) Molecular mechanisms of mitochondrial dysfunction, including bioenergetic failure and redox imbalance;

(2) Cellular consequences, such as neuronal damage, synaptic impairment, and apoptosis; and

(3) Translational and therapeutic implications, including pharmacological and molecular interventions targeting mitochondrial pathways.

This classification enabled systematic comparison of findings across different biological levels and disease contexts.

The primary outcome of interest was the identification of key mitochondrial dysfunction pathways contributing to neuronal damage and neurodegenerative disease progression. Secondary outcomes included the effects of mitochondrial impairment on synaptic plasticity, neuronal survival, and clinical manifestations,

as well as the evaluation of emerging therapeutic strategies targeting mitochondrial processes.

A translational evaluation framework was incorporated to assess the clinical applicability of findings. This involved analyzing the relationship between molecular mechanisms and observable clinical outcomes, such as cognitive decline, motor dysfunction, and disease progression. Studies demonstrating direct correlations between mitochondrial parameters and clinical features were prioritized.

Data synthesis was conducted using both qualitative and semi-quantitative approaches. Qualitative analysis focused on identifying recurring patterns in mitochondrial dysfunction and its effects on neural systems, while semi-quantitative synthesis summarized trends in mitochondrial parameters and disease associations across studies. Cross-study comparisons were used to identify consistent mechanisms and potential sources of variability.

Potential sources of bias were critically evaluated, including heterogeneity in experimental methodologies, variability in mitochondrial measurement techniques, and differences in patient populations. Studies employing standardized assays, longitudinal designs, or multi-center data were considered more robust and were given greater weight in the analysis.

Ethical considerations were also incorporated into the methodological framework. All included studies adhered to established ethical standards, including institutional approval and informed consent where applicable. Broader ethical issues related to mitochondrial research—such as the use of experimental models and the translation of findings to human populations—were also considered.

Overall, this methodological approach provides a rigorous and comprehensive foundation for investigating mitochondrial dysfunction in neurological disorders,

enabling a detailed analysis of its molecular mechanisms, cellular consequences, and translational therapeutic potential.

Results

The integrative analysis demonstrates that mitochondrial dysfunction is a central and unifying mechanism underlying neuronal damage and disease progression across a wide spectrum of neurological disorders. Evidence from molecular, cellular, and clinical studies consistently indicates that disruptions in mitochondrial bioenergetics, dynamics, and signaling pathways contribute significantly to neurodegeneration.

A key finding is that mitochondrial dysfunction occurs early in disease progression and often precedes overt neuronal loss. Across multiple studies, reductions in mitochondrial efficiency and alterations in mitochondrial structure were detected in preclinical stages of disorders such as Alzheimer's disease and Parkinson's disease. This suggests that mitochondrial impairment is not merely a consequence of neuronal damage but an active driver of disease initiation.

Graph 1: ATP Production Levels in Neurological Disorders



Global Conference on Medical and Health Sciences
Hosted Online from Madrid, Spain
Date: 14th April, 2026
Website: https://econferencia.com



The graph illustrates a significant decline in ATP production across major neurological disorders compared to healthy controls. Alzheimer's disease shows progressive ATP reduction associated with mitochondrial impairment in cortical neurons, while Parkinson's disease demonstrates marked energy deficits in dopaminergic neurons. Amyotrophic lateral sclerosis is characterized by widespread ATP depletion in motor neurons.

This reduction in energy availability compromises essential neuronal functions, including synaptic transmission, ion homeostasis, and intracellular signaling. The findings highlight bioenergetic failure as a central component of neuronal dysfunction and a key contributor to disease progression.

Another critical result is the increased production of reactive oxygen species (ROS) associated with mitochondrial dysfunction.

Graph 2: ROS Generation and Oxidative Stress in Mitochondrial Dysfunction





Global Conference on Medical and Health Sciences
Hosted Online from Madrid, Spain
Date: 14th April, 2026
Website: https://econferencia.com



The graph demonstrates elevated ROS levels in neurological disorders, reflecting increased oxidative stress due to mitochondrial impairment. Dysfunctional electron transport chains lead to electron leakage and excessive ROS generation, which damages cellular components.

This oxidative burden contributes to lipid peroxidation, protein oxidation, and DNA damage, further impairing mitochondrial function and creating a self-amplifying cycle of cellular injury. The findings reinforce the close relationship between mitochondrial dysfunction and oxidative stress in neurodegeneration.

A major finding is the disruption of mitochondrial dynamics and quality control mechanisms.

Graph 3: Alterations in Mitochondrial Dynamics (Fission, Fusion, Mitophagy)



Global Conference on Medical and Health Sciences
Hosted Online from Madrid, Spain
Date: 14th April, 2026
Website: https://econferencia.com



The graph highlights imbalances in mitochondrial dynamics, including increased fission, reduced fusion, and impaired mitophagy. These alterations lead to the accumulation of damaged mitochondria and reduced cellular resilience.

In Parkinson's disease, defects in mitophagy pathways—particularly involving PINK1 and Parkin proteins—result in the inability to remove dysfunctional mitochondria. In Alzheimer's disease, altered fission and fusion dynamics contribute to mitochondrial fragmentation and impaired energy production.

The findings emphasize the importance of mitochondrial quality control in maintaining neuronal health and preventing disease progression.

Another significant result is the role of mitochondrial dysfunction in calcium dysregulation and apoptosis.

Graph 4: Calcium Dysregulation and Apoptotic Pathways



Global Conference on Medical and Health Sciences
Hosted Online from Madrid, Spain
Date: 14th April, 2026
Website: https://econferencia.com



The graph illustrates increased mitochondrial calcium accumulation and activation of apoptotic pathways in neurological disorders. Calcium overload disrupts mitochondrial membrane potential and triggers the release of pro-apoptotic factors such as cytochrome c.

This process activates caspase-dependent cell death pathways, leading to neuronal apoptosis. The findings demonstrate that mitochondrial dysfunction not only impairs cellular function but also directly contributes to neuronal loss.

In addition to these findings, the analysis revealed that mitochondrial dysfunction interacts with other pathological processes, including oxidative stress, neuroinflammation, and protein aggregation. These interactions create a complex network of self-reinforcing mechanisms that accelerate neurodegeneration.

Another important observation is the variability of mitochondrial dysfunction across individuals and disease types, influenced by genetic factors, environmental exposures, and disease stage. This variability highlights the need for personalized approaches to treatment.

Despite strong evidence supporting the role of mitochondrial dysfunction in neurological disorders, several limitations were identified. Differences in experimental models, measurement techniques, and patient populations may

affect the consistency of findings. Additionally, the complexity of mitochondrial biology makes it challenging to establish direct causal relationships.

Nevertheless, the overall results provide robust evidence that mitochondrial dysfunction is a central driver of neuronal damage and disease progression. By linking molecular mechanisms to cellular dysfunction and clinical outcomes, this study highlights the importance of targeting mitochondrial pathways for therapeutic intervention.

Discussion

The findings of this study provide strong and integrative evidence that mitochondrial dysfunction represents a central and convergent mechanism underlying neuronal damage and the progression of neurological disorders. By synthesizing molecular, cellular, and clinical data, the results support a comprehensive framework in which mitochondrial impairment acts not only as a downstream consequence of disease processes but also as a primary driver of neurodegeneration.

One of the most significant insights emerging from this analysis is the early involvement of mitochondrial dysfunction in disease pathogenesis. The consistent observation of reduced ATP production, altered mitochondrial dynamics, and increased oxidative stress in preclinical stages suggests that mitochondrial impairment may precede overt neuronal loss. This challenges traditional models that primarily focus on protein aggregation or synaptic dysfunction as initiating factors and highlights the importance of mitochondrial pathways in the earliest phases of disease.

The central role of bioenergetic failure is particularly noteworthy. Neurons are highly dependent on continuous ATP supply for maintaining ion gradients, synaptic transmission, and intracellular signaling. The observed decline in ATP

production compromises these essential processes, leading to impaired neuronal function and increased vulnerability to damage. This energy deficit represents a critical link between molecular dysfunction and clinical manifestations, such as cognitive decline and motor impairment.

The interplay between mitochondrial dysfunction and oxidative stress further amplifies neuronal damage. Dysfunctional mitochondria generate excessive reactive oxygen species, which in turn damage mitochondrial components and further impair their function. This creates a self-perpetuating cycle of oxidative stress and mitochondrial impairment, accelerating disease progression. The findings highlight the importance of targeting both mitochondrial function and oxidative stress in therapeutic strategies.

Another key implication of this study is the disruption of mitochondrial dynamics and quality control mechanisms. The imbalance between mitochondrial fission and fusion, along with impaired mitophagy, leads to the accumulation of damaged mitochondria. This accumulation reduces cellular resilience and increases susceptibility to stress. In particular, the impairment of mitophagy pathways in diseases such as Parkinson's disease underscores the importance of mitochondrial quality control in maintaining neuronal health.

The role of mitochondrial dysfunction in calcium dysregulation and apoptosis provides a direct link to neuronal loss. The observed calcium overload and activation of apoptotic pathways demonstrate how mitochondrial impairment can trigger cell death mechanisms. This finding is particularly important in understanding the irreversible nature of neurodegenerative diseases, where progressive neuronal loss leads to clinical deterioration.

From a translational perspective, the findings underscore the potential of mitochondrial pathways as therapeutic targets. Strategies aimed at enhancing mitochondrial function, restoring energy production, reducing oxidative stress,

and improving mitochondrial dynamics hold promise for slowing or preventing disease progression. However, the complexity of mitochondrial biology presents significant challenges for therapeutic development.

The limited success of current mitochondrial-targeted therapies highlights the need for more precise and mechanism-based approaches. Factors such as timing of intervention, specificity of therapeutic agents, and patient heterogeneity must be carefully considered. Personalized medicine approaches that account for individual differences in mitochondrial function may be particularly important in improving treatment outcomes.

Despite these promising implications, several challenges remain. The heterogeneity of mitochondrial dysfunction across different neurological disorders and patient populations complicates the identification of universal therapeutic targets. Additionally, the dynamic nature of mitochondrial processes makes it difficult to establish clear causal relationships between mitochondrial dysfunction and disease progression.

Methodological variability across studies also represents a limitation. Differences in measurement techniques, experimental models, and study designs can contribute to inconsistencies in findings. Standardization of research methodologies is essential for improving reproducibility and facilitating clinical translation.

Ethical considerations also play an important role in the application of mitochondrial research. The use of biomarkers for early detection raises questions regarding patient counseling, data interpretation, and management of preclinical diagnoses. Ensuring equitable access to advanced diagnostic and therapeutic technologies is essential for preventing disparities in healthcare outcomes.

From a broader perspective, the findings highlight the importance of interdisciplinary research in advancing our understanding of neurological

disorders. Integrating insights from molecular biology, neuroscience, and clinical medicine is essential for developing comprehensive models of disease and effective therapeutic strategies.

In conclusion, mitochondrial dysfunction represents a central and integrative mechanism in neurological disorders, linking molecular damage to cellular dysfunction and clinical outcomes. By providing a detailed understanding of mitochondrial processes and their role in disease progression, this study highlights the potential for innovative therapeutic approaches aimed at restoring mitochondrial function and improving patient outcomes. Continued research focused on refining these strategies and overcoming translational challenges will be essential for advancing precision medicine in neurology.

Conclusion

The present study establishes mitochondrial dysfunction as a central and convergent mechanism underlying neuronal damage and the progression of neurological disorders, offering a comprehensive and integrative framework that links molecular alterations to clinical outcomes. By synthesizing evidence from molecular biology, cellular neuroscience, and clinical research, the findings demonstrate that mitochondrial impairment is not merely a secondary consequence of disease processes but a primary driver of neurodegeneration.

A major contribution of this work lies in highlighting the early involvement of mitochondrial dysfunction in disease pathogenesis. The consistent observation of reduced ATP production, increased oxidative stress, and disrupted mitochondrial dynamics in early disease stages suggests that mitochondrial impairment may precede overt neuronal loss. This underscores the importance of early detection and intervention strategies targeting mitochondrial pathways.

Furthermore, the study emphasizes the critical role of mitochondrial bioenergetics in maintaining neuronal function. The decline in ATP production compromises essential processes such as synaptic transmission, ion homeostasis, and intracellular signaling, leading to progressive neuronal dysfunction. The interplay between mitochondrial dysfunction and oxidative stress further amplifies cellular damage, creating a self-perpetuating cycle that accelerates disease progression.

The disruption of mitochondrial dynamics, including imbalances in fission, fusion, and mitophagy, represents another key mechanism contributing to neuronal vulnerability. The accumulation of damaged mitochondria and impaired quality control processes reduce cellular resilience and increase susceptibility to stress. These findings highlight the importance of mitochondrial maintenance systems in preserving neuronal integrity.

From a translational perspective, mitochondrial dysfunction represents a promising target for therapeutic intervention. Strategies aimed at enhancing mitochondrial function, reducing oxidative stress, and restoring mitochondrial dynamics hold significant potential for slowing disease progression and improving clinical outcomes. However, the complexity of mitochondrial biology and variability among patients necessitate the development of precise and individualized therapeutic approaches.

Despite these advances, several challenges remain. The heterogeneity of mitochondrial dysfunction across different neurological disorders, lack of standardized measurement techniques, and complexity of mitochondrial signaling pathways limit the immediate translation of research findings into clinical practice. Additionally, ethical considerations related to early diagnosis and treatment must be carefully addressed.

In conclusion, mitochondrial dysfunction represents a critical and integrative mechanism in neurological disorders, providing valuable insights into disease pathogenesis and potential therapeutic targets. Continued interdisciplinary research and translational efforts will be essential for advancing precision medicine and improving outcomes for patients with neurological diseases.

References

1. Eric R. Kandel et al. (2021). *Principles of Neural Science*. McGraw-Hill.
2. Dale Purves et al. (2018). *Neuroscience*. Oxford University Press.
3. Allan H. Ropper (2019). *Principles of Neurology*. McGraw-Hill.
4. Даминов, Б. Т., & Ортикбоев, Ж. О. (2020). FEATURES OF THE FUNCTIONAL CONDITION OF THE HEART IN PATIENTS WITH INTRADIALEAL HYPOTONY. Новый день в медицине, (2), 78-81.
5. ОРТИКБОЕВ, Ж., & ШОЮНУСОВ, С. (2020). АСПЕКТЫ БРОНХИАЛЬНОЙ АСТМЫ. ББК 60 И 66, 144.
6. Khasanov, U. S., Djuraev, J. A., Vokhidov, U. N., Khujanov, S. K., Botirov, A. Z., & Shaumarov, A. Z. (2022). Результаты анализа частоты распределение полиморфизма a1188c rs3212227 в гене il 12b среди пациентов с хроническим полипозным риносинуситом. Oriental Journal of Medicine and Pharmacology, 2(1), 104-115.
7. Нормуродов, Б. К., Джураев, Д. А., Шаумаров, А. З., & Ахмедов, Д. М. (2020). Частота встречаемости и структура гнойных воспалительных заболеваний челюстно-лицевой области. Хирург, (7-8), 73-84.
8. Хасанов, У. С., Вохидов, У. Н., Джураев, Ж. А., Шаумаров, А. З., & Шарипов, С. С. (2020). Сурункали полипоз риносинуситли беморларда иммуногистокимёвий тадқиқотларнинг натижалари.

9. Normurodov, B. K., Djuraev, J. A., Shaumarov, A. Z., & Akhmedov, J. M. (2020). Prevalence and structure of purulent inflammatory diseases of the maxillofacial area. Central Asian Journal of Medicine, 2020, 116-130.

10. Djuraev, J. A., Khasanov, U. S., Nuridinovuch, V. U., & Zavkievich, S. A. (2021). Results of Frequency Analysis Distribution of Polymorphism Rs1800895 592c> A In Il10 Gene among Patients with Chronic Polypoid Rhinosinusitis. The International Tinnitus Journal, 25(2), 176-180.

11. Djuraev, J. A., Khasanov, U. S., Vokhidov, U. N., Botirov, A. J., Akhundjanov, N. A., & Ergashev, U. M. & Shaumarov, AZ (2021). Distribution of Allel Variants and Genotypes of Il4, Il10, Il12b, Tlr2 Genes in the Group of Patients with CPRS. Annals of the Romanian Society for Cell Biology, 4466-4470.

12. Ортикбоев, Ж. О., Газиева, Х. Ш., & Ортикбоева, Ш. О. (2019). Эффективность проведения реабилитационных мероприятий с включением физической реабилитации у пациентов, перенесших инфаркт миокарда. Евразийский кардиологический журнал, (S1), 59.

13. Хакимов, Д. П., Рустамов, А. А., Фахриев, Ж. А., & Сафаров, З. Ф. (2017). Структура травматических повреждений у детей, пострадавших вследствие дорожно-транспортных происшествий. Молодой ученый, (22), 422-425.

14. Агзамходжаев, Т. С., Расулова, Х. А., Шорахмедов, Ш. Ш., & Ортикбоев, Ж. О. (2020). DIAGNOSTIC ADVANTAGES OF CONTACTLESS BIOIMPEDANESOMETRY. Новый день в медицине, (2), 293-300.

15. Ортикбоев, Ж. О., Ортикбоева, Ш. О., & Олимхонова, К. Н. (2019). Клинико-лабораторные и инструментальные особенности влияния

артериальной гипертонии на течение сахарного диабета. Евразийский кардиологический журнал, (S1), 124-125.

16. Jurakulovich, K. O., Ogli, O. J. O., Golibovna, K. G., & Bahromdjanovna, A. N. (2015). Peculiarities of dermatoglyphic values among the people of Uzbek population dependently on sex. European journal of biomedical and life sciences, (2), 35-38.

17. Ортикбоев, Ж. О., & Асадов, Н. З. (2025). СОВРЕМЕННЫЕ ПОДХОДЫ К ПРОФИЛАКТИКЕ ПРОГРЕССИРОВАНИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: КЛИНИКО-ПАТОГЕНЕТИЧЕСКОЕ ОБОСНОВАНИЕ. ОСНОВЫ МЕДИЦИНЫ, 1(5), 45-51.

18. Атаходжаева, Г. А., Мирзалиева, А. А., & Султонов, С. С. (2020). Клинико-лабораторные особенности хронической сердечной недостаточности у больных мебаболическим синдромом. *Academic research in educational sciences*, (3), 541-550.

19. Рахимов, Ш. М., & Атаходжаева, Г. А. (2009). Реакция тромбоцитов на гелиогеофизические факторы у больных стабильной стенокардией в зависимости от их толерантности к физической нагрузке. *Фундаментальные исследования*, (7), 37-40.

20. Шадманова, Н. К., Рахимов, Ш. М., & Атаходжаева, Г. А. (2012). Гемодинамическая эффективность бисопролола и моксонидина и его взаимосвязь с вегетативной регуляцией у больных гипертонической болезнью при различных гелиогеофизических условиях. *Врач-аспирант*, *53*(4.2), 317-327.

21. Атаходжаева, Г. А., & Баратова, Д. С. (2017). Состояние качества жизни и толерантности к физической нагрузке больных с хронической сердечной недостаточностью II-III функционального класса при

применении антагонистов минералокортикоидных рецепторов. *Молодой ученый*, (4), 235-239.

22. Atakhodjaeva, G. A., Rakhimov, S. M., & Azimova, N. Z. (2017). Вариабельность ритма сердца у больных с хронической сердечной недостаточностью и метаболическим синдромом. *Likars' ka sprava*, (3-4), 31-37.

23. Атаходжаева, Г. А. (2021). Особенности функционального состояния почек у больных с артериальной гипертензией и сахарным диабетом 2 типа: научное издание. *Терапевтический вестник Узбекистана: научно-практический журнал.–Ташкент: ЗАО СЕАЛ МАГ*, (1), 96-99.

24. Alyavi, A. L., Rakhimova, D. A., Atakhodzhaeva, G. A., Sabirzhanova, Z. T., Gazieva, H. S., & Usmanova, U. S. (2021). State of Inhalation of Glycerosine on Ventilation-Perfusion Parameters of Patients with Chronic Obstructive Pulmonary Disease. *Annals of the Romanian Society for Cell Biology*, *25*(1), 707-711.

25. Атаходжаева, Г. А., Турсунбаев, А. К., & Собиров, Х. Г. (2017). Состояние центральной и внутрисердечной гемодинамики при остром коронарном синдроме. *Молодой ученый*, (4), 239-245.

26. Kamilova, U. M. I. D. A., Atakhodjaeva, G. U. L. C. H. E. K. H. R. A., Abdullaeva Ch, M. D., Zakirova, G., & Tagaeva, D. (2022). Features in the processes of left ventricular remodeling depending on the degree of renal dysfunction in patients with chronic heart failure. *Int J Biomed*, *12*(2), 218-21.

27. Атаходжаева, Г. А., Рахимов, Ш. М., & Азимова, Н. З. (2017). Вариабельность ритма сердца у больных с хронической сердечной недостаточностью и метаболическим синдромом. *Врачебное дело*, (3-4), 31-37.

28. Atakhodzhaeva, G. A. (2015). Rakhimov Sh. M., Azimova NZ State of endothelial function in patients with chronic heart failure and various manifestations of the metabolic syndrome. *Kardiologiya i serdechno-sosudistaya khirurgiya*, *8*(3), 76-80.

29. Агзамходжаев, Т. С., Расулова, Х. А., Шорахмедов, Ш. Ш., & Ортикбоев, Ж. О. (2020). DIAGNOSTIC ADVANTAGES OF CONTACTLESS BIOIMPEDANESOMETRY. Новый день в медицине, (2), 293-300.

30. Ортикбоев, Ж. О., Ортикбоева, Ш. О., & Олимхонова, К. Н. (2019). Клинико-лабораторные и инструментальные особенности влияния артериальной гипертонии на течение сахарного диабета. Евразийский кардиологический журнал, (S1), 124-125.

31. Jurakulovich, K. O., Ogli, O. J. O., Golibovna, K. G., & Bahromdjanovna, A. N. (2015). Peculiarities of dermatoglyphic values among the people of Uzbek population dependently on sex. European journal of biomedical and life sciences, (2), 35-38.

32. Ортикбоев, Ж. О., & Асадов, Н. З. (2025). СОВРЕМЕННЫЕ ПОДХОДЫ К ПРОФИЛАКТИКЕ ПРОГРЕССИРОВАНИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: КЛИНИКО-ПАТОГЕНЕТИЧЕСКОЕ ОБОСНОВАНИЕ. ОСНОВЫ МЕДИЦИНЫ, 1(5), 45-51.

33. Ilkhamova, D., Makhkamova, M., Ortikboev, J., Makhkamova, L., & Nasimjanova, M. (2024). Diagnostics Of The Current Psychological Status Of Children With Chronic Somatic Diseases. SPAST Reports, 1(1).

34. Ортикбоев, Ж. О. (2020). ЭТИОПАТОГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ РАЗВИТИЯ СИНДИАЛИЗНОЙ ГИПОТОНИИ У БОЛЬНЫХ, ПОЛУЧАЮЩИХ ГЕМОДИАЛИЗ. Новый день в медицине, (4), 78-84.

35. Ilkhamova, D., Makhkamova, M., Ortikboev, J., Makhkamova, L., & Nasimjanova, M. (2024). Diagnostics Of The Current Psychological Status Of Children With Chronic Somatic Diseases. SPAST Reports, 1(1).
36. Ортикбоев, Ж. О. (2020). ЭТИОПАТОГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ РАЗВИТИЯ СИНДИАЛИЗНОЙ ГИПОТОНИИ У БОЛЬНЫХ, ПОЛУЧАЮЩИХ ГЕМОДИАЛИЗ. Новый день в медицине, (4), 78-84.
37. Kaplan & Sadock (2021). *Comprehensive Textbook of Psychiatry*.
38. Joseph LeDoux (2020). *The Deep History of Ourselves*.
39. Patricia Churchland (2019). *Braintrust*.
40. Mark S. Greenberg (2020). *Handbook of Neurosurgery*.
41. Ian Goodfellow et al. (2016). *Deep Learning*. MIT Press.
42. Kevin P. Murphy (2022). *Probabilistic Machine Learning*. MIT Press.
43. Aurélien Géron (2022). *Hands-On Machine Learning*.
44. Peter Norvig & Stuart Russell (2021). *Artificial Intelligence: A Modern Approach*.
45. Christoph Molnar (2022). *Interpretable Machine Learning*.
46. Judea Pearl (2018). *The Book of Why*.
47. Daniel Kahneman (2011). *Thinking, Fast and Slow*.
48. Ethem Alpaydin (2021). *Machine Learning*.
49. Christopher Bishop (2006). *Pattern Recognition and Machine Learning*.
50. Trevor Hastie (2017). *Statistical Learning*.
51. Thomas M. Mitchell (2017). *Machine Learning*.
52. Michael Wooldridge (2021). *A Brief History of AI*.
53. Eric Topol (2019). *Deep Medicine*.
54. Gerd Gigerenzer (2018). *Risk Savvy*.
55. Cass R. Sunstein (2020). *Too Much Information*.

56. Paul Cerrato (2020). *Mobile Medicine*.
57. Oxford Editors (2019). *Oxford Handbook of Clinical Neuroscience*.
58. T.H. Jones (2018). *Clinical Neurology*.
59. Setti S. Rengachary (2019). *Principles of Neurosurgery*.
60. David J. Hand (2020). *The Improbability Principle*.
61. Sebastian Raschka (2019). *Python Machine Learning*.
62. Andrew Ng (2022). *Machine Learning Yearning*.
63. Douglas C. Wallace (2021). *Mitochondrial Biology and Medicine*.